Jesse Richman, MD
Ophthalmology · Providence, RINPI 1346402872
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Alcon at 40.4% of the total. Among ophthalmology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $274.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$12K
- AbbVie$7K
- Rxsight Inc$6K
- Ivantis, Inc$3K
- Alcon Research LLC$980
- Glaukos Corporation$327
- plus $711 from 9 others
What the payments were for
- Consulting fees$16,64155%
- Speaking & faculty fees$9,76232%
- Food & beverage$3,93913%
- Education$580%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 60 | $12,282 |
| AbbVie(2 entities) | 18 | $7,067 |
| Rxsight Inc | 8 | $6,404 |
| Ivantis, Inc | 5 | $2,647 |
| Alcon Research LLC | 1 | $980 |
| Glaukos Corporation | 2 | $327 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $285 |
| Sight Sciences, Inc. | 4 | $268 |
| Bausch & Lomb Americas Inc. | 3 | $45 |
| NEW World Medical,inc. | 2 | $29 |
| Harrow Eye, LLC | 1 | $21 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$12,553
- RXSIGHT CONTACT LENS$6,243
- RXSIGHT INJECTOR CARTRIDGE$6,243
- LIGHT ADJUSTABLE LENS (LAL)$6,243
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$6,243
- RXSIGHT INJECTOR HANDPIECE$6,243
- DURYSTA$3,850
- XEN GLAUCOMA TREATMENT SYSTEM$2,851
- Hydrus$633
- Clareon$251
- Tecnis IOL$248
- iStent infinite Trabecular Micro-Bypass System Model iS3$199
- Tecnis Simplicity$147
- iStent inject W$128
- OMNI$125
- OMNI(R) SURGICAL SYSTEM (US)$114
- SIMBRINZA$112
- Rhopressa$112
- Rocklatan$112
How this compares
$30,417 in reported general payments places this provider in the 95th percentile of 69 ophthalmology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 124 | $74,861 |
| VyzultaLatanoprostene Bunod | 176 | $67,515 |
| CombiganBrimonidine Tartrate/Timolol | 67 | $40,848 |
| Prednisolone Acetate | 1,273 | $39,397 |
| RhopressaNetarsudil Mesylate | 60 | $23,936 |
| Alphagan PBrimonidine Tartrate | 43 | $22,867 |
| MoxifloxacinMoxifloxacin Hcl | 924 | $20,913 |
| Travoprost | 81 | $20,139 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 77 | $19,374 |
| RocklatanNetarsudil Mesylat/Latanoprost | 57 | $18,712 |
| Ketorolac Tromethamine | 958 | $14,593 |
| RestasisCyclosporine | 11 | $8,298 |
| AzoptBrinzolamide | 18 | $7,854 |
| Restasis MultidoseCyclosporine | 12 | $7,828 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 62 | $7,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis, Restasis Multidose | $7,067 | $154,702257 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $45 | $67,515176 claims |
| AlconSimbrinza, Azopt | $12,282 | $27,22995 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 ophthalmology providers in Rhode Island.
Other ophthalmology in Providence
- Sarah AnisProvidence$163K
- Yoash EnzerProvidence$11K
- David TienProvidence$6K
- Jane CookProvidence$4K
- Christopher NewtonProvidence$3K
- Joseph DucharmeProvidence$3K
- King ToProvidence$2K
- Gaurav GuptaProvidence$2K
- Carolina ChiouProvidence$2K
- Ezra GallerProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.